What is the current stock price of Q BioMed Inc. (QBIO)?

As of the latest market data, Q BioMed Inc. (QBIO) is trading at $0.00. The stock has seen a loss of -0.00% today.

Does Q BioMed Inc. (QBIO) pay a dividend?

Based on current data, Q BioMed Inc. does not have a confirmed active dividend policy.

What is the market cap of Q BioMed Inc.?

The current market capitalization of Q BioMed Inc. (QBIO) is approximately unavailable.

QBIO

Q BioMed Inc.·Healthcare

0.00

0.000%(−0.00)

Market Closed

Last Updated: — ET

52W L: $0.0052W H: $0.03

QBIO NEWS

defenseworld.net

6d ago

Q Biomed (OTCMKTS:QBIO) vs. GeneDx (NASDAQ:WGS) Financial Comparison

GeneDx (NASDAQ: WGS - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings. Risk and Volatility GeneDx has a beta of 2.17,

defenseworld.net

Feb 10

Establishment Labs (NASDAQ:ESTA) & Q Biomed (OTCMKTS:QBIO) Critical Contrast

Establishment Labs (NASDAQ: ESTA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk. Valuation and Earnings This table compares Establishment Labs

defenseworld.net

Jan 19

Q Biomed (OTCMKTS:QBIO) & Auna (NYSE:AUNA) Head to Head Review

Auna (NYSE: AUNA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Volatility and Risk Auna has a beta of 2.26,

Company Profile

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2015-06-17

Beta

-154.93

Websitewww.qbiomed.com↗